Krónikus lymphoid leukaemia fludarabin kezeléséhez társuló súlyos immun-thrombocytopenia sikeres, rituximab és nagy adag immunglobulinnal történt kombinált kezelése

Translated title of the contribution: Successful combined treatment with rituximab and high dose immunoglobulin in a patient with chronic lymphocytic leukemia associated with fludarabine-induced severe immune thrombocytopenia

Béla Telek, Péter Batár, M. Udvardy

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Chronic lymphocytic leukemia is rarely associated with immune thrombocytopenia. Although fludarabine treatment is widely used in the treatment of chronic lymphocytic leukemia, it can also increase the incidence and severity of immune thrombocytopenia. The authors present a case of chronic lymphocytic leucaemia after relapse of the disease. Fludarabine + cyclophosphamide treatment was administered which resulted in a nearly complete hematological remission but severe immune thrombocytopenia has occurred (platelet count <5 × 109/l). Conventional steroid and immunosuppressive treatment have failed and, in addition, autoimmune hemolysis has developed after six weeks. Rituximab (375 mg/m2) and high dose intavenous immunglobuline treatment was started and platelet count has increased (40 × 109/l). Prolonged (> 1.5 year) remission and subsided hemolysis have been observed due to the rituximab treatment. Successful treatment of choice can be rituximab in those cases of chronic lymphocytic leukemia which previously have been treated with fludarabine and associated with severe immune thrombocytopenia.

Original languageHungarian
Pages (from-to)1791-1793
Number of pages3
JournalOrvosi Hetilap
Volume146
Issue number34
Publication statusPublished - 2005

Fingerprint

Idiopathic Thrombocytopenic Purpura
B-Cell Chronic Lymphocytic Leukemia
Immunoglobulins
Therapeutics
Hemolysis
Platelet Count
Cyclophosphamide
fludarabine
Rituximab
Recurrence
Incidence

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{287dd809ef5244b4802a27c1d1c8ff35,
title = "Kr{\'o}nikus lymphoid leukaemia fludarabin kezel{\'e}s{\'e}hez t{\'a}rsul{\'o} s{\'u}lyos immun-thrombocytopenia sikeres, rituximab {\'e}s nagy adag immunglobulinnal t{\"o}rt{\'e}nt kombin{\'a}lt kezel{\'e}se",
abstract = "Chronic lymphocytic leukemia is rarely associated with immune thrombocytopenia. Although fludarabine treatment is widely used in the treatment of chronic lymphocytic leukemia, it can also increase the incidence and severity of immune thrombocytopenia. The authors present a case of chronic lymphocytic leucaemia after relapse of the disease. Fludarabine + cyclophosphamide treatment was administered which resulted in a nearly complete hematological remission but severe immune thrombocytopenia has occurred (platelet count <5 × 109/l). Conventional steroid and immunosuppressive treatment have failed and, in addition, autoimmune hemolysis has developed after six weeks. Rituximab (375 mg/m2) and high dose intavenous immunglobuline treatment was started and platelet count has increased (40 × 109/l). Prolonged (> 1.5 year) remission and subsided hemolysis have been observed due to the rituximab treatment. Successful treatment of choice can be rituximab in those cases of chronic lymphocytic leukemia which previously have been treated with fludarabine and associated with severe immune thrombocytopenia.",
keywords = "Chronic lymphocytic leukemia, Fludarabine, Immune thrombocytopenia, Rituximab",
author = "B{\'e}la Telek and P{\'e}ter Bat{\'a}r and M. Udvardy",
year = "2005",
language = "Hungarian",
volume = "146",
pages = "1791--1793",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "34",

}

TY - JOUR

T1 - Krónikus lymphoid leukaemia fludarabin kezeléséhez társuló súlyos immun-thrombocytopenia sikeres, rituximab és nagy adag immunglobulinnal történt kombinált kezelése

AU - Telek, Béla

AU - Batár, Péter

AU - Udvardy, M.

PY - 2005

Y1 - 2005

N2 - Chronic lymphocytic leukemia is rarely associated with immune thrombocytopenia. Although fludarabine treatment is widely used in the treatment of chronic lymphocytic leukemia, it can also increase the incidence and severity of immune thrombocytopenia. The authors present a case of chronic lymphocytic leucaemia after relapse of the disease. Fludarabine + cyclophosphamide treatment was administered which resulted in a nearly complete hematological remission but severe immune thrombocytopenia has occurred (platelet count <5 × 109/l). Conventional steroid and immunosuppressive treatment have failed and, in addition, autoimmune hemolysis has developed after six weeks. Rituximab (375 mg/m2) and high dose intavenous immunglobuline treatment was started and platelet count has increased (40 × 109/l). Prolonged (> 1.5 year) remission and subsided hemolysis have been observed due to the rituximab treatment. Successful treatment of choice can be rituximab in those cases of chronic lymphocytic leukemia which previously have been treated with fludarabine and associated with severe immune thrombocytopenia.

AB - Chronic lymphocytic leukemia is rarely associated with immune thrombocytopenia. Although fludarabine treatment is widely used in the treatment of chronic lymphocytic leukemia, it can also increase the incidence and severity of immune thrombocytopenia. The authors present a case of chronic lymphocytic leucaemia after relapse of the disease. Fludarabine + cyclophosphamide treatment was administered which resulted in a nearly complete hematological remission but severe immune thrombocytopenia has occurred (platelet count <5 × 109/l). Conventional steroid and immunosuppressive treatment have failed and, in addition, autoimmune hemolysis has developed after six weeks. Rituximab (375 mg/m2) and high dose intavenous immunglobuline treatment was started and platelet count has increased (40 × 109/l). Prolonged (> 1.5 year) remission and subsided hemolysis have been observed due to the rituximab treatment. Successful treatment of choice can be rituximab in those cases of chronic lymphocytic leukemia which previously have been treated with fludarabine and associated with severe immune thrombocytopenia.

KW - Chronic lymphocytic leukemia

KW - Fludarabine

KW - Immune thrombocytopenia

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=32944455652&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=32944455652&partnerID=8YFLogxK

M3 - Article

C2 - 16184881

AN - SCOPUS:32944455652

VL - 146

SP - 1791

EP - 1793

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 34

ER -